Human CD137 & NF-κB Reporter Recombinant Cell Line, HEK293 (CAT#: IOC-LX137)

Creative Biolabs has developed several immune checkpoint stable cell Lines expressing the most popular immune checkpoints to accelerate clients' immunotherapy discovery and clinical translation. Recombinant HEK293 cell line expressing a full length human CD137 (4-1BB) (NM_001561). The NF-κB luciferase reporter construct is stably integrated into the genome. The firefly luciferase gene is controlled by 4 copies of NF-κB response element located upstream of the TATA promoter. Following activation by human CD137 ligand, NF-κB transcription factors bind to the DNA response elements to induce transcription of the luciferase gene. Which can be used in binding assays and functional assay.

Stable cell lines for increased reliability and reproducibility;
Protein expression at the cell surface validated by FACS or WB;

Screen for activators or inhibitors of CD137 signaling in a cellular context and characterize the biological activity of CD137 and its interactions with ligands.

Human

HEK293

CD137 & NF-κB Reporter

Human CD137 (4-1BB; TNFRS9) is an inducible co-stimulatory molecule that activates T cells. CD137:CD137L-mediated signaling has been shown to be important for proliferation, effector functions and survivals of T cells. CD137 is also expressed in NK and NKT cells. Accumulating evidence shows a role for CD137:CD137L signaling in inflammation, suggesting that inhibition of this pathway may provide a therapeutic avenue to treat autoimmune and inflammatory diseases. Similarly, antibodies targeting CD137 activation in immune cells have demonstrated potent anti-tumor properties in cancer patients.